|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 22, 2017 ) This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.
For more information about this report: http://www.reportsweb.com/Neuropsychiatric-Disorder-Cluster-Drug-Development-Pipeline-Review,-2017
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.
Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.
The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.
Scope
- Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics-
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
- What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders-
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001978884/sample
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Publisher Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 12
Introduction 13
Neuropsychiatric Disorder Cluster Report Coverage 13
Attention Deficit Hyperactivity Disorder (ADHD)-Overview 13
Depression-Overview 13
Schizophrenia-Overview 13
Tourette Syndrome-Overview 13
Therapeutics Development 14
Attention Deficit Hyperactivity Disorder (ADHD) 14
Depression 22
Schizophrenia 36
Tourette Syndrome 47
Therapeutics Assessment 50
Attention Deficit Hyperactivity Disorder (ADHD) 50
Depression 57
Schizophrenia 68
Tourette Syndrome 78
Companies Involved in Therapeutics Development 84
Attention Deficit Hyperactivity Disorder (ADHD) 84
Depression 101
Schizophrenia 148
Tourette Syndrome 185
Dormant Projects 189
Attention Deficit Hyperactivity Disorder (ADHD) 189
Depression 192
Schizophrenia 201
Tourette Syndrome 206
Discontinued Products 207
Attention Deficit Hyperactivity Disorder (ADHD) 207
Depression 208
Schizophrenia 211
Tourette Syndrome 212
Product Development Milestones 213
Attention Deficit Hyperactivity Disorder (ADHD) 213
Depression 224
Schizophrenia 233
Tourette Syndrome 243
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001978884/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
